87 related articles for article (PubMed ID: 26573829)
1. High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients.
Imamura M; Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Sakita I; Hatada T; Takatsuka Y; Katagiri T; Miyoshi Y
Breast Cancer Res Treat; 2015 Dec; 154(3):521-31. PubMed ID: 26573829
[TBL] [Abstract][Full Text] [Related]
2. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
3. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
Igawa T; Sakai H; Kanetake H; Saito Y
Hinyokika Kiyo; 1999 Apr; 45(4):235-9. PubMed ID: 10363141
[TBL] [Abstract][Full Text] [Related]
4. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
5. Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.
Izumi K; Mizokami A; Itai S; Shima T; Shigehara K; Miwa S; Maeda Y; Konaka H; Koh E; Namiki M
BJU Int; 2012 Feb; 109(3):394-400. PubMed ID: 21599822
[TBL] [Abstract][Full Text] [Related]
6. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14.
Lipton A; Chapman JA; Demers L; Shepherd LE; Han L; Wilson CF; Pritchard KI; Leitzel KE; Ali SM; Pollak M
J Clin Oncol; 2011 Sep; 29(27):3605-10. PubMed ID: 21859992
[TBL] [Abstract][Full Text] [Related]
7. Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases.
Shizuku M; Shibata M; Okumura M; Takeuchi D; Kikumori T; Mizuno Y
Breast Cancer; 2020 Nov; 27(6):1065-1071. PubMed ID: 32415556
[TBL] [Abstract][Full Text] [Related]
8. Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer.
Kiuchi K; Ishikawa T; Hamaguchi Y; Momiyama N; Hasegawa S; Ishiyama A; Kono T; Doi T; Chishima T; Shimada H
Oncol Rep; 2002; 9(3):595-8. PubMed ID: 11956634
[TBL] [Abstract][Full Text] [Related]
9. Carboxy-terminal propeptide of type 1 procollagen (P1CP) and carboxy-terminal telopeptide of type 1 collagen (1CTP) as sensitive markers of bone metabolism in thyroid disease.
Miyakawa M; Tsushima T; Demura H
Endocr J; 1996 Dec; 43(6):701-8. PubMed ID: 9075610
[TBL] [Abstract][Full Text] [Related]
10. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
11. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
12. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
13. Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma.
Nabeya Y; Shimada H; Okazumi S; Matsubara H; Gunji Y; Suzuki T; Ochiai T
Cancer; 2002 Feb; 94(4):940-9. PubMed ID: 11920462
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma.
Izumi M; Nakanishi Y; Takayama K; Kimotsuki K; Inoue K; Wataya H; Minami T; Hara N
Cancer; 2001 Apr; 91(8):1487-93. PubMed ID: 11301396
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.
Tamiya M; Kobayashi M; Morimura O; Yasue T; Nakasuji T; Satomu M; Kohei O; Takayuki S; Morishita N; Suzuki H; Sasada S; Okamoto N; Hirashima T; Kawase I
Clin Lung Cancer; 2013 Jan; 14(1):50-4. PubMed ID: 22609050
[TBL] [Abstract][Full Text] [Related]
16. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
17. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
18. Measurement of serum marker for bone metastasis (1-CTP) in hepatobiliary and pancreas malignancies.
Nanashima A; Takeshita H; Tobinaga S; Araki M; Sumida Y; Kunizaki M; Tanaka K; Abo T; Hidaka S; Sawai T; Yasutake T; Nagayasu T
Hepatogastroenterology; 2010; 57(101):694-7. PubMed ID: 21033212
[TBL] [Abstract][Full Text] [Related]
19. [Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type 1 collagen (1CTP)--some basic aspects of the RIA kit and clinical evaluation in various bone diseases].
Yamamoto I; Takada M; Yuu I; Ohnaka Y; Kigami Y; Yamamoto Y; Hamazu H; Morita R
Kaku Igaku; 1993 Nov; 30(11):1411-7. PubMed ID: 8277604
[TBL] [Abstract][Full Text] [Related]
20. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
